Katie F. Maass - Concepedia

Author

Katie F. Maass

Massachusetts Institute of Technology ORCID

Also Known As

K MAASS, K Maass, K. Maass, Katie F. Maass, Stephanie L. Lin

Publications

903

Citations

H-Index

Concepts

All Affiliations

Massachusetts Institute of Technology Johns Hopkins Medicine Pfizer (United States)California Retina Consultants Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Katie F. Maass is an author at Massachusetts Institute of Technology specializing in medicine, pharmacology, and biomedical engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	234
2	Engineering	3	3	72
3	Health Sciences	1	1	46
4	Natural Sciences	1	1	16
5	Public Health	1	1	38

Katie F. Maass

Publications

784

Citations

H-Index

Page 1

	Year	Citations
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Peter A. Campochiaro, Dennis M. Marcus, Carl C. Awh, Ophthalmology	2019	262
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Nancy M. Holekamp, Peter A. Campochiaro, Margaret Chang, Ophthalmology	2021	169
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design Katie F. Maass, Chethana Kulkarni, Alison Betts, The AAPS Journal Immunocytochemical TechniqueMedicineCellular Processing RatesBioanalysisImmunology	2016	75
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality Katie F. Maass, Matthew Barfield, Mototsugu Ito, Clinical and Translational Science Blood SamplesPatient SelectionClinical EndpointVenous Blood DrawTranslational Medicine	2022	46
Will patient-centric sampling become the norm for clinical trials after COVID-19? Christopher James, Matthew Barfield, Katie F. Maass, Nature Medicine Patient SelectionCovid-19 PandemicPatient SafetyClinical TrialsRandomized Controlled Trial	2020	38
Dynamic swelling behavior of interpenetrating polymer networks in response to temperature and pH Brandon V. Slaughter, Aaron T. Blanchard, Katie F. Maass, Journal of Applied Polymer Science Tissue EngineeringEngineeringIonic PolymersSmart PolymerResponsive Polymers	2015	33
Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration Arshad M. Khanani, Vrinda Hershberger, Dante J. Pieramici, American Journal of Ophthalmology	2021	32
In-vitro characterization of ranibizumab release from the Port Delivery System Stefan T. Yohe, Katie F. Maass, Judit Horvath, Journal of Controlled Release	2022	21
Hybrid responsive hydrogel carriers for oral delivery of low molecular weight therapeutic agents Mary Caldorera‐Moore, Katie F. Maass, Rachel A. Hegab, Journal of Drug Delivery Science and Technology Biopolymer GelNanomedicineHydrogelsEngineeringOral Delivery	2015	20
Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye Devin B. Tesar, Jacob Luoma, Emily A. Wyatt, mAbs Ocular DiseaseEngineeringLong-acting DeliveryBiomedical EngineeringRetinal Therapies	2017	19

Page 1